Novo Nordisk said on Monday an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary ...

The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.